Integra Completes Acquisition of Acclarent

On Apr 2, 2024

Integra LifeSciences Holdings Corporation of Princeton has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent’s product portfolio expands the breadth of Integra’s brands and provides immediate scale and accretive growth via a dedicated sales channel. The acquisition adds $1 billion to the total addressable market of the company’s offerings, while providing unique market opportunities for access to the attractive ENT device segment.

“Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, enabling us to deliver transformative technologies to restore patients’ lives,” said Mike McBreen, executive vice president and president, Codman Specialty Surgical division. “We are looking forward to working alongside our Acclarent colleagues to make a profound impact on ENT and neurosurgery care.”

The company will release its first quarter 2024 financial results and provide second quarter and full-year guidance, inclusive of the Acclarent business, on Thursday, April 25, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences offers a comprehensive portfolio of brand products that include Acclarent®, AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, NeuraWrap™, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®.

To access more business news, visit NJB News Now.

Related Articles: